The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Simon D. Pollett*, Stephanie A. Richard, Anthony C. Fries, Mark P. Simons, Katrin Mende, Tahaniyat Lalani, Tida Lee, Sharon Chi, Rupal Mody, Cristian Madar, Anuradha Ganesan, Derek T. Larson, Christopher J. Colombo, Rhonda Colombo, Emily C. Samuels, Christopher C. Broder, Eric D. Laing, Darci R. Smith, David Tribble, Brian K. AganTimothy H. Burgess

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Little is known about severe acute respiratory syndrome coronavirus 2 "vaccine-breakthrough"infections (VBIs). Here we characterize 24 VBIs in predominantly young healthy persons. While none required hospitalization, a proportion endorsed severe symptoms and shed live virus as high as 4.13 × 103 plaque-forming units/mL. Infecting genotypes included both variant-of-concern (VOC) and non-VOC strains.

Original languageEnglish
Pages (from-to)897-900
Number of pages4
JournalClinical Infectious Diseases
Volume74
Issue number5
DOIs
StatePublished - 1 Mar 2022
Externally publishedYes

Keywords

  • SARS-CoV-2
  • live virus
  • patient-reported outcomes
  • symptoms
  • vaccine breakthrough

Fingerprint

Dive into the research topics of 'The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity'. Together they form a unique fingerprint.

Cite this